IL6 and head and neck squamous cell carcinoma: In a subgroup of HNSCC, the ex vivo targeting αVβ3 and αVβ5 integrins by cilengitide and EGFR by cetuximab leads to reduced CFec and release of IL-6 and MCP-1, thus proving that cilengitide in binary combination with cetuximab does have potential in the treatment of this subgroup.